The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain.

Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

[5] DR5 has been shown to interact with: Monoclonal antibodies targeting DR5 have been developed and are currently under clinical trials for patients suffer from a variety of cancer types, see Tigatuzumab (CS-1008).

Luminescent iridium complex-peptide hybrids, serving as TRAIL mimics, have been designed, which target the death receptors DR4 and DR5 on cancer cells and induce their apoptosis.

[12] This article incorporates text from the United States National Library of Medicine, which is in the public domain.